Immuno-Oncolytic Viruses

In recent years, oncolytic immunotherapy has shown great promise in the fight against cancer challenged by specificity and accuracy problems.

Oncolytic Viruses can fight malignant tumor cells by selective replication within the tumor, resulting in a direct destruction of the malignant cells. The cell remnants spread through the body and induce anti-tumor immunity. These viruses can also destroy blood vessels that nurture the tumor and induce an anti-tumor response by artificially expressing immune-related transgenes.

However, if not sufficiently controlled, Oncolytic Viruses are largely ineffective. While the viruses can help promote an immune response against the tumor cells, neutralizing antiviral responses may block virus replication and ongoing infection of tumor cells. 

Therefore, the key challenges are fine-tuning the immune response to maximize virus spread and anticancer immunity, and manufacturing viruses with orders-of-magnitude higher titters. 

 

SynVaccine’s technology does exactly that

Synvaccine's engine is the first fully integrated computer-aided design and manufacturing (CAD/CAM) system for synthetic, rationally designed viruses.

 

By studying and formulating the natural evolutionary laws of viruses, designing a virus with the desired specifications, and manufacturing it with a unique two-way validation process, SynVaccine is able to fine-tune the selectivity and replication rate of the virus, and control the expressed transgene. The result is a highly efficient and accurate Oncolytic Virus.

 

Oncolytic Immunotherapy has great promise in the fight against cancer, wanting only for for accuracy. Now, SynVaccine is turning it from a blunt apparatus to a precise instrument.

Oncolytic Virus Therapy